1. Effects of acute and chronic administration of MK-801 on c-Fos protein expression in mice brain regions implicated in schizophrenia with or without clozapine
- Author
-
Haifeng Wang, Dai-Ying Zuo, Yue Cao, Ying-Liang Wu, and Lan Zhang
- Subjects
Male ,medicine.medical_specialty ,Psychosis ,Gene Expression ,Mice ,Internal medicine ,Cortex (anatomy) ,medicine ,Animals ,Prefrontal cortex ,Clozapine ,Biological Psychiatry ,Brain Chemistry ,Pharmacology ,business.industry ,Glutamate receptor ,Genes, fos ,medicine.disease ,Immunohistochemistry ,Dizocilpine ,Endocrinology ,medicine.anatomical_structure ,Posterior cingulate ,Schizophrenia ,NMDA receptor ,Dizocilpine Maleate ,business ,Excitatory Amino Acid Antagonists ,Proto-Oncogene Proteins c-fos ,Antipsychotic Agents ,medicine.drug - Abstract
This study investigated the effects of acute and chronic administration of the non-competitive NMDA receptor antagonists MK-801 on c-Fos protein expression in different brain regions of mice with or without clozapine. MK-801 (0.6 mg/kg) acute administration produced a significant increase in the expression of c-Fos protein in the layers III-IV of posterior cingulate and retrosplenial (PC/RS) cortex, which was consistent with the previous reports. Moreover, we presented a new finding that MK-801 (0.6 mg/kg) chronic administration for 8 days produced a significant increase of c-Fos protein expression in the PC/RS cortex, prefrontal cortex (PFC) and hypothalamus of mice. Among that, c-Fos protein expression in the PC/RS cortex of mice was most significant. Compared to acute administration, we found that MK-801 chronic administration significantly increased the expression of c-Fos protein in the PC/RS cortex, PFC and hypothalamus. Furthermore, pretreatment of mice with clozapine significantly decreased the expression of c-Fos protein induced by MK-801 acute and chronic administration. These results suggest that c-Fos protein, the marker of neuronal activation, might play an important role in the chronic pathophysiological process of schizophrenic model induced by NMDA receptor antagonist.
- Published
- 2009